Paolo Tarantino: What’s distinct about Breast cancers with ERBB2?
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, posted on X about recent paper by him as co-author, titled “Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2” published on ESMO OPEN.
Authors: X. Qiu, P. Tarantino, R. Li, A. Grinshpun, H. Gupta, M.E. Hughes, G. Kirkner, L. Scholl, B.E. Johnson, M. Meyerson, A.D. Cherniack, Y. Jiang, N. Zhou, N.U. Lin, H.W. Long, S.M. Tolaney, R. Jeselsohn
“Breast cancers with ERBB2 het loss appear resistant to T-DXd. But what’s distinct about these tumors?
By leveraging multiple cohorts, we show that ERBB2del tumors have:
- Increased TP53 loss
- Increased proliferation and immune signaling
- Decreased HER2 mRNA
- Decreased ER signaling
- Decreased survival.”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School. He completed a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023